FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.